Sunshine Biopharma Reports 4.1% Revenue Increase in Fiscal 2025

The pharmaceutical company saw $36.3 million in revenue last year as it continues developing life-saving drugs.

Apr. 6, 2026 at 3:00pm

Got story updates? Submit your updates here. ›

Sunshine Biopharma Inc., a pharmaceutical company focused on oncology, antivirals, and other life-saving medicines, reported fiscal year 2025 revenue of $36.3 million, a 4.1% increase over the prior year. The company remains committed to reaching profitability in the near future.

Why it matters

Sunshine Biopharma's revenue growth demonstrates the company's ability to commercialize its drug pipeline and generate consistent financial performance, which is crucial for a pharmaceutical firm developing innovative treatments. The company's focus on life-saving medicines also highlights its mission to address critical healthcare needs.

The details

Sunshine Biopharma, a NASDAQ-listed company, reported $36.3 million in revenue for fiscal year 2025, up 4.1% from the previous year. The company is developing a range of pharmaceutical products across oncology, antivirals, and other therapeutic areas to bring life-saving medicines to market.

  • Sunshine Biopharma reported its fiscal year 2025 financial results on April 6, 2026.

The players

Sunshine Biopharma Inc.

A pharmaceutical company offering and developing life-saving medicines across oncology, antivirals, and other therapeutic areas. The company is listed on the NASDAQ stock exchange.

Got photos? Submit your photos here. ›

The takeaway

Sunshine Biopharma's revenue growth and focus on developing life-saving drugs demonstrate the company's ability to execute on its pharmaceutical pipeline and address critical healthcare needs, positioning it for potential future profitability.